New Coronavirus Vaccine (COVID-19 Vaccines) Development

 

Novel Corona Virus Vaccine (COVID-19 Vaccines)

The new coronavirus vaccine is a vaccine against the new coronavirus.

On January 24, 2020, the Chinese Center for Disease Control and Prevention successfully isolated China’s first strain of new coronavirus strain. At 20:18 on March 16, the recombinant new crown vaccine was approved to start clinical trials. On April 13, China’s new coronavirus vaccine entered phase II clinical trials. On the same day, an expert group composed of more than 120 scientists, doctors, funders and manufacturers around the world issued a public declaration, promising to coordinate under the World Health Organization, work together to speed up the development of the new crown vaccine. On June 19th, China's first new crown mRNA vaccine was approved to start clinical trials. As of July 20, there are currently about 250 candidate new coronavirus vaccines in development worldwide, of which at least 17 vaccines are in clinical trials.

What are the Developments in Coronavirus Vaccines production?

On August 5, 2020, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products affiliated to Sinopharm Group passed the joint biosafety inspection organized by the relevant state departments and is qualified for use. 

Previously, the workshop had obtained the new crown vaccine production license; on August 16, the team of Academician Chen Wei obtained a patent for the new crown vaccine, which is the first in China. This invention patent application enjoys a priority review policy.

On the 20th, the clinical trial of the China Biotech Covid-19 inactivated vaccine under the Sinopharm Group was launched in Peru (Phase III).

On October 8, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the “New Coronary Pneumonia Vaccine Implementation Plan”.

As of October 20, 2020, China has vaccinated a total of about 60,000 subjects, and no serious adverse reactions have been reported.

What is the Latest news on COVID Vaccines?

China's vaccine research and development is in the world's first phalanx 2020-12-16 23:41

Recently, “China currently has 5 new coronavirus vaccines undergoing phase III clinical trials, and the number is among the highest in the world.” Zheng Zhongwei, head of the vaccine research and development team of the Joint Prevention and Control Mechanism Research Team of the State Council, said in an exclusive interview with Xinhua News Agency reporters. Vaccine research and development has entered the sprint stage. We are in the first square in the world, but we are not rushing for the first place." 

"Evaluating a vaccine requires multiple comprehensive indicators, among which safety, effectiveness, accessibility, and affordability are Most importantly."

Table of Contents on 2019-nCoV vaccine

1. R & D process

2. Research and development

▪ Global

▪ Domestic

▪ abroad

3. R & D progress

▪ Separation of virus species

▪ Clinical trials

4. Vaccine application

5. Vaccine exports

6. Social impact

7. disputes

What are the R&D Processes of COVID19 Vaccine?

The general process and cycle of vaccine research and development include two stages:

The first stage is the pre-vaccine development process, including obtaining immunogens (obtaining live viruses, isolating related subunits, obtaining recombinant proteins through genetic recombination technology or synthesizing related DNA (RNA)), immune response testing, animal protection testing, and immunization 

The original production process (amplification) optimization, pre-clinical toxicological research and other links.

The second stage is the vaccine development and registration process, including pre-clinical research, clinical application, and clinical trials, and finally the vaccine can be marketed.

What is the Development Global Status on Coconavirus Vaccines?

As of June 27, 2020, there are more than 200 vaccine candidates worldwide, 15 of which are undergoing human clinical trials.

On July 20, 2020, there are currently about 250 candidate new coronavirus vaccines in the world, and at least 17 vaccines are in clinical trials.

On January 24, the Chinese Center for Disease Control and Prevention has successfully isolated China's first strain of the new coronavirus. 

The Chinese National Pathogenic Microorganism Resource Bank released the virus species information and electron micrographs of this virus (New Coronavirus Wuhan Strain 01), as well as important authoritative information such as primers and probe sequences for nucleic acid detection of the novel coronavirus. These have laid the foundation for the development of vaccines.

On January 26, Xu Wenbo, director of the Institute of Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, said that the center has started the research and development of a new coronavirus vaccine, has successfully isolated the virus, and is screening seed strains.

On January 28, it was learned from the Oriental Hospital Affiliated to Tongji University that the translational medicine platform of the Oriental Hospital Affiliated to Tongji University cooperated with Siwei (Shanghai) Biotechnology Co., Ltd., relying on the "Shanghai Zhangjiang National Independent Innovation Demonstration Zone Stem Cell Strategy Bank and the clinical transformation of stem cell technology.

The sub-task of the "Platform" project-the results of the mRNA synthesis platform, quickly promote the development of new coronavirus mRNA vaccines. The project has been urgently completed for registration.

On February 15th, in accordance with the decision and deployment of the Party Central Committee, under the leadership of the Central Leading Group for Response to the Epidemic and the Joint Prevention and Control Mechanism of the State Council, the scientific research team set out to deploy vaccine research and development tasks. 

The vaccine research and development class under the scientific research team was established.

It was reported on February 26 that the Fujian Provincial Department of Science and Technology established a project to support the “Research on New Coronavirus Candidate Vaccines and Quality Control Methods” project of Xiamen University, to develop new coronary pneumonia vaccines from two technical routes of attenuated vector vaccines and genetic engineering recombinant vaccines.

On March 17, Wang Junzhi, an academician of the Chinese Academy of Engineering, said at a press conference of the Joint Prevention and Control Mechanism of the State Council that China is carrying out emergency development of the new crown vaccine in accordance with five technological routes.

On March 18, Zhong Nanshan, the leader of the high-level expert group of the National Health Commission and academician of the Chinese Academy of Engineering, said at the Guangzhou epidemic prevention and control conference that the Chinese new crown pneumonia vaccine has passed animal experiments and will be used in human clinical trials.

On March 21, according to public information on the China Clinical Trial Registration Center, the sponsors of the trial were the Institute of Bioengineering, Academy of Medical Sciences, Academy of Military Sciences and Kansino Biotech.

On April 9, the adenovirus vector vaccine of the Academy of Military Medicine of the Academy of Military Sciences began to recruit volunteers for the second phase clinical trial. It is the world's first new coronavirus vaccine to start the second phase clinical trial.

On April 12, the new coronavirus inactivated vaccine jointly applied by Sinopharm Wuhan Institute of Biological Products and Wuhan Institute of Virology, Chinese Academy of Sciences was approved to enter clinical trials.

On April 13, the inactivated vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. was approved. 

On April 14, the scientific research team of the State Council’s Joint Prevention and Control Mechanism stated that China’s two inactivated vaccines for the new coronavirus have obtained the combined clinical trial licenses for the first and second phases of the National Medical Products Administration, and related clinical trials have started simultaneously. 

This is the first batch of inactivated vaccines for the new coronavirus to be approved for clinical research. 

The two new coronavirus inactivated vaccines were developed by Sinopharm Wuhan Institute of Biological Products and Beijing Kexing Zhongwei Biotechnology Co., Ltd. in conjunction with relevant scientific research institutions. 

On May 26, the international authoritative medical journal The Lancet published a paper introducing the positive results of the first phase clinical trial of a new coronavirus vaccine candidate developed by the Chinese team. 

Volunteers vaccinated with 3 different doses of candidate vaccines all produced neutralizing antibodies against the new coronavirus and T cell immune responses, and showed good tolerance; within 28 days after vaccination, most people's neutralizing antibodies increased More than 4 times.

 

On June 5, the fully human monoclonal antibody developed by Gao Fu et al. entered clinical trials.

On June 16, the blind review of phase I/II clinical trials of the new coronavirus inactivated vaccine developed by the Wuhan Institute of Biological Products of China National Pharmaceutical Group and the phased unblinding meeting were held simultaneously in Beijing and Henan. 

Experts from the State Council's Joint Prevention and Control Mechanism Vaccine Class and the Biotechnology Development Center of the Ministry of Science and Technology attended. 

The unblinding results showed that the safety after vaccination was good. 

There was no serious adverse reaction. After different procedures and different doses, the vaccinated persons in the vaccine group all produced high-titer antibodies.

After two doses of 28-day program; neutralizing antibody positive conversion The rate is 100%.

On June 19, the Novel Coronavirus mRNA Candidate Vaccine (ARCoV) jointly developed by the Academy of Military Medicine of the Academy of Military Sciences and local enterprises has officially passed the clinical trial approval of the National Medical Products Administration. 

This is the first mRNA vaccine approved for clinical trials in China. On the same day, the National Medical Products Administration approved the new crown recombinant protein vaccine jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilong Kema to enter clinical trials. 

This is after the adenovirus vector vaccine and inactivated vaccines entered clinical trials. The new crown vaccine developed by another new technical route has entered the clinical trial stage.

On June 28, Gao Fu and other scholars published a study online in the top international academic journal "Cell", entitled "A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS", providing a The universal design of β-coronavirus vaccines against COVID-19, MERS and SARS.

On June 29, Cansino Biological Co., Ltd. announced that the recombinant new coronavirus vaccine (adenovirus vector) was approved for military special needs.

On July 20, the Chinese research team published a paper in the British medical journal The Lancet, saying that they conducted a phase 2 clinical trial of a new coronavirus vaccine. The results showed that the vaccine is safe and can induce immunity in the human body.

On July 22, Zheng Zhongwei, director of the Science and Technology Development Center of the National Health Commission and the leader of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said in the program that my country has officially launched the emergency use of the new crown vaccine. 

The purpose of emergency use is to establish an immune barrier among special populations such as medical personnel, epidemic prevention personnel, border inspection personnel, and personnel who guarantee basic urban operations, so that the operation of the entire city will have a stable guarantee.

On August 5, according to the latest news from Sinopharm Group, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products passed the joint biosafety inspection organized by the relevant state departments and was qualified for use. 

Previously, the workshop had obtained a new crown vaccine production license.

On August 16, according to the State Intellectual Property Office, the new crown vaccine (Ad5-nCoV) patent application jointly filed by the team of Academician Chen Wei of the Academy of Military Medical Research of the Academy of Military Sciences and Cansino Biotechnology has been granted patent rights. This is China The first new crown vaccine patent.

On August 19, according to the State Intellectual Property Office, after verification, the vaccine patent application was titled "a recombinant new coronavirus vaccine using human replication-deficient adenovirus as a vector", the patent application number is 202010193587.8, and the applicant is The Academy of Military Sciences of the Chinese People’s Liberation Army Academy of Military Sciences and Kansino Biological Co., Ltd., the inventor is Chen Wei, etc., and the application date is March 18, 2020. 

After submitting a priority review request, the State Intellectual Property Office on August 11, 2020 After issuing a patent authorization notice, the bureau will announce the authorization of the patent after the applicant has completed the patent registration procedures in accordance with the law.  

On August 20 and August 21, Sinopharm Sinopharm signed cooperation agreements with Peru, Morocco and Argentina on phase III clinical trials of the new crown inactivated vaccine and held the launch ceremony. 

This marks a comprehensive acceleration of the Phase III clinical trials of China's new biological new crown inactivated vaccine. More sample sizes and clinical trial data in different regions will greatly enhance the marketing process of the new crown inactivated vaccine.

On September 25, the State Council Information Office briefed. Wu Yuanbin, director of the Department of Science and Technology for Social Development of the Ministry of Science and Technology, revealed that 11 new coronavirus vaccines in my country are currently in clinical trials. Four vaccines entered Phase III clinical trials, of which three were inactivated vaccines and one was adenovirus vector vaccine.

On September 25, the State Council Information Office held a briefing. Wu Yuanbin, director of the Department of Social Development and Science of the Ministry of Science and Technology, revealed at the meeting that 11 new coronavirus vaccines in China have entered clinical trials. 

Four vaccines entered Phase III clinical trials, of which three were inactivated vaccines and one was adenovirus vector vaccine. Recombinant protein vaccines, nucleic acid vaccines, and attenuated influenza virus vector vaccines are stepping up to carry out phase I and phase II clinical trials.

On October 20, Tian Baoguo, deputy director of the Department of Social Development and Science and Technology of the Ministry of Science and Technology, said at a press conference on the Joint Prevention and Control Mechanism of the State Council that China has four new coronavirus vaccines that have entered the phase III clinical trial.

Covid-19 Vaccine Development Country Wise 

1. COVID Vaccines Development in Australia

It was reported on January 22, 2020 that the University of Queensland in Australia is using a patented technology to quickly produce a vaccine against the new coronavirus. 

Keith Chapel of the University of Queensland, one of the leaders of the scientific research project, told Xinhua News Agency that the school’s research team has obtained the genetic sequence of the new coronavirus and is in the early stages of developing a related vaccine. 

This patented technology called "molecular tweezers" developed by the research team of the University of Queensland can increase the stability of viral proteins. 

The research team tried to use this technology to develop targets against Middle East respiratory syndrome coronavirus, Nipah virus, Ebola virus and The influenza virus vaccine has achieved very ideal experimental results.

2. COVOD Vaccines development in the United States

On February 19, 2020, Sanofi Pasteur, the global vaccine division of Sanofi, announced that it will cooperate with the US Biomedical Advanced Research and Development Agency (BARDA) to accelerate development using an advanced genetic recombination technology platform The new coronavirus (COVID-19) vaccine.

On March 2, 2020, the University of California, Riverside issued a statement stating that the research team found the drug target protein in the new coronavirus and cracked the 3D structure of the protein, which will help develop treatments for the new coronavirus, drugs for pneumonia. 

The research team consists of researchers from the University of California, Riverside, the University of Chicago, the U.S. Department of Energy Argonne National Laboratory and Northwestern University.

On April 7, 2020, a US company announced that the US Food and Drug Administration (FDA) has accepted the company's new drug clinical trial (IND) application for the new coronavirus candidate DNA vaccine INO-4800.

On May 5, 2020, Pfizer of the United States has begun testing an experimental vaccine in the United States to combat the new coronavirus.

3. Development of COVID Vaccines in Russia

On February 26, 2020, Russian Deputy Prime Minister Golikova told the media that Russian researchers have obtained the new coronavirus strain and have developed 5 prototype vaccines against the virus. 

The Russian "Vector" National Science Center for Virology and Biotechnology has developed five prototype vaccines against the new coronavirus, but they are still in the initial stage of vaccine development.

On March 20, 2020, the Russian Federation Biomedical Agency issued an announcement stating that its experts are stepping up the development of vaccines against the new coronavirus and have developed 3 prototype vaccines.

On August 1, 2020, Russian Health Minister Murashko stated that the new crown vaccine will be vaccinated for free. Murashko said: "We plan and budget to fully cover the cost of the new crown vaccination. The vaccination plan is to vaccinate as planned." 

Murashko also said that Russia will be vaccinated on a large scale in October, and doctors and teachers are given priority. At the same time, the government will monitor vaccinated people.

On August 11, 2020, according to the Russian Satellite News Agency, the Russian Minister of Health stated that the first registered new crown virus vaccine was named "Satellite-V" (SPUTNIK V), and pointed out that vaccination of the new crown virus vaccine can make people develop long-term Immunity, which can last for two years, is expected to start circulation on January 1, 2021.

4. Coronavirus Vaccine Development in Israel

On February 27, 2020, the Israeli Ministry of Science and Technology announced that the country’s researchers are accelerating the development of an oral novel coronavirus vaccine, which is expected to start clinical trials within 90 days. 

Israeli Minister of Science and Technology Ophir Akunis said that the institution that is developing this vaccine is the Miguel Galilee Institute, and the Ministry of Science and Technology will speed up all approval procedures related to this vaccine to promote the vaccine's early launch.

In June 2020, the Israel Institute of Biology announced the completion of animal experiments for the new crown vaccine. On November 1, two Israeli hospitals vaccinated two volunteers with a new crown vaccine called "BriLife" developed by the Israel Institute of Biology.

5. Development of Coronavirus Vaccine in Korea

On March 4, 2020, the Korean Institute of Chemistry stated that the new virus fusion research team led by the institute has found neutralizing antibodies against the new coronavirus, which will help advance the process of developing a new coronavirus vaccine.

6. Development of COVID19 Vaccine in Germany

According to a report on March 15, 2020, CureVac, a biopharmaceutical company headquartered in Tübingen, Germany, said that using its vaccine development platform based on messenger ribonucleic acid (mRNA) technology, it is expected to develop effective candidates against the new coronavirus within a few months vaccine. 

During this time, the governments of the United States and Germany attached great importance to the company's ability to rapidly develop and produce vaccines, competing for funding and secretly competing against possible future vaccine supplies.

7. Development of Coronavirus Vaccine in the United Kingdom

On March 17, 2020, the University of Cambridge in the United Kingdom said that a team at the school is using artificial intelligence, synthetic biology and other technologies to accelerate the development of a new coronavirus vaccine. 

According to Professor Jonathan Heney, who led the team, the vaccine may be used in clinical trials as early as June. Prior to this, the research teams at Oxford University and Imperial College in the United Kingdom also expressed that they are working hard to develop vaccines.

8. Development of Coronavirus Vaccine in South Africa

On June 23, 2020, South Africa's Golden Mountain University announced at an online press conference that South Africa will start the first clinical trial of the new crown vaccine on the African continent. 

The vaccine used in the trial was developed by the Jenner Institute of Oxford University, and is currently undergoing clinical trials in the UK.

Covid Vaccines R&D progress

Separation of virus species

On January 24, 2020, the National Pathogenic Microorganism Resource Bank released information on China’s first virus strain successfully isolated by the Institute for Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, as well as its electron microscopy photos, new coronavirus nucleic acid detection primers and probes Sequence and other important authoritative information released for the first time in China, and provide shared services.  

Clinical Trials for COVID19 Vaccines

Clinical Trial for Coronavirus Vaccines in China

At 20:18 on March 16, 2020, a scientific research team led by Academician Chen Wei of the Academy of Military Medicine of the Academy of Military Sciences was approved to start clinical trials.

 

Phase I trial

There are not many volunteers needed for the Phase I trial. They are limited to permanent residents in Wuhan. Residents with registered permanent residence in Wuchang, Hongshan, and Donghu Scenic Areas are preferred, aged 18-60 years old. 

Volunteers will be divided into three groups, low-dose group, medium-dose group and high-dose group, with 36 people in each group. After screening and physical examination, qualified volunteers can be vaccinated. The following 14 days will be the centralized isolation observation period.

On March 31, 2020, the first batch of volunteers vaccinated with the recombinant new coronavirus vaccine (adenovirus vector) has reached the 14-day medical observation period. 

As of April 2, 108 subjects in the Phase I clinical trial of the new crown vaccine in Wuhan have all completed vaccination, and 18 of them have ended their isolation. Everyone must have a CT scan when they are released from isolation, and they are in good physical condition.

The Phase I clinical study recruited a small number of subjects to evaluate the safety of the vaccine and whether it can produce an immune response.

Phase II trial

On April 9, 2020, the Phase II clinical study of the new crown vaccine launched volunteer recruitment. The phase II clinical study selected low- and medium-dose vaccines for the trial. 

The study was divided into 3 groups, namely the medium-dose vaccine group (250 cases), the low-dose vaccine group (125 cases) and the placebo control group (125 cases). 

Both the vaccine and the placebo control were jointly developed by the Institute of Bioengineering of the Academy of Military Medicine of the Academy of Military Sciences and Kansino Biotech. 

According to the requirements of the research protocol, each volunteer must complete a research visit on the day of vaccination, the 14th day, the 28th day, and the 6th month, and a total of four blood samples are required. 

The phase II clinical study has a moderate number of subjects to adjust and improve the procedures and procedures of clinical vaccination, and obtain statistical data such as adverse reactions.

On April 13, 2020, the new coronavirus vaccine entered the phase II clinical trial. The phase II clinical trial of the recombinant new coronavirus vaccine was led by the Jiangsu Provincial Center for Disease Control and completed by the Hubei Provincial Center for Disease Control and Zhongnan Hospital. In clinical trials, volunteers do not need to undergo 14-day intensive observation.

Phase III trial

Phase III clinical studies mainly evaluate the effectiveness of the vaccine and recruit larger-scale subjects to confirm that the vaccine can achieve the expected purpose of preventing infection or reducing symptoms.

On August 20, 2020, the clinical trial of the China Bio-New Crown Inactivated Vaccine under Sinopharm Group was launched in Peru (Phase III). 

After obtaining the UAE clinical trial approval on June 23, it has been awarded the Phase III clinical trial approval by the National Institutes of Health of the Ministry of Health of Peru.  

On November 11, 2020, good news came from the research and development of the domestically produced new crown vaccine: the world's first inactivated new crown vaccine phase III clinical trial progressed smoothly.

Sinopharm’s official WeChat account announced that the Phase III clinical trial of Sinopharm’s China Bio-New Crown Vaccine is progressing smoothly in UAE, Bahrain, Egypt, Jordan, Morocco, Peru, Argentina and other countries, and has entered the final sprint stage, with more than 50,000 volunteers inoculating The sample population covers 125 nationalities.

Clinical Trial for Coronavirus Vaccines in United States

On February 24, 2020, the American biotechnology company Modena announced that it has shipped the company’s first batch of new coronavirus vaccine mRNA-1273 to the National Institute of Allergy and Infectious Diseases for the first phase of clinical trials. 

On March 5, 2020, according to the official announcement of the American biotechnology company Moderna, the U.S. Food and Drug Administration (FDA) has completed the review of the company’s new coronavirus mRNA vaccine-"mRNA-1273" and approved its entry Clinical Trials.

On March 16, 2020, the National Institutes of Health said that a new coronavirus vaccine developed in the United States began the first phase of clinical trials on the same day, and the first volunteers enrolled in the group have received experimental vaccine injections.

Coronavirus Vaccines Application

COVID Vaccine Application in China

On October 8, 2020, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the "New Coronary Pneumonia Vaccine Implementation Plan." This is an important measure for China to uphold the concept of a community of human health and fulfill its commitment to promote vaccines as a global public product.

In October 2020, the new crown vaccine will not be included in the medical insurance, but the new crown pneumonia related treatment drugs will be included in the new scope of the medical insurance catalog.

On the afternoon of October 15, 2020, the Jiaxing Center for Disease Control and Prevention of Zhejiang Province released the "Instructions for New Coronary Vaccination" on its official WeChat. 

The new coronavirus vaccination is administered in 2 doses with an interval of 14-28 days. The vaccine price is 200 yuan per tube. The total dose is 400 yuan.

As of October 20, 2020, China has vaccinated a total of about 60,000 subjects, and no serious adverse reactions have been reported.

International COVID Vaccine Implementation

On December 2, 2020, the Japanese Senate held a meeting. At the meeting, the amendment to the "Vaccination Law" was unanimously passed, including that the cost of nationals to vaccinate the new crown vaccine shall be borne by the state. 

If health problems occur after vaccination, the state will reach an agreement with the pharmaceutical company, and the latter will compensate for it. The government subsidized the losses of pharmaceutical companies after the fact.

Coronavirus Vaccine export

On October 14, 2020, Venezuelan President Nicolas Maduro stated that the country will receive China's new crown vaccine in the next few days. At the same time, it is expected that by April 2021, the Venezuelan government will launch large-scale free vaccination work.

On October 15, 2020, according to the Wall Street Journal, a senior health official in Indonesia said that Indonesia is taking measures to approve China’s new crown vaccine candidates for emergency use, which will make Indonesia the second country outside of China to do so. 

Previously, the UAE has approved a Chinese new crown vaccine for emergency use.

On October 23, 2020, the Brazilian Health Surveillance Agency (ANVISA) stated in a statement that it had authorized the Biomedical Center of the Butantan Institute of Sao Paulo to import 6 million doses developed by China Beijing Kexing Biological Products Co., Ltd. (Sinovac) The new crown vaccine.

Social influence

COVID19 Vaccine Declaration

On April 13, 2020, an expert group composed of more than 120 scientists, doctors, funders and manufacturers around the world issued a public declaration, promising to work together to accelerate the development of the new crown vaccine under the coordination of the World Health Organization.

The declaration stated that as part of international cooperation in the fight against the epidemic, these scientists, doctors, funders and manufacturers will, under the coordination of the WHO, work together to promote the accelerated "access" of the new crown vaccine. 

Although it takes time to develop a universal vaccine, the vaccine will ultimately play an important role in controlling this global pandemic.

The declaration said that during this period, experts called for community interventions to reduce the spread of the virus and protect the people, including vulnerable groups, and promised to use the time gained by taking such measures to develop vaccines as soon as possible.

The declaration said: "We will continue to work hard to strengthen the unprecedented global collaboration, cooperation and data sharing already underway. We believe that these efforts will help reduce inefficiency and duplication of labor. We will make unremitting efforts to improve the Everyone offers the possibility of one or more safe and effective vaccines.

In July 2020, Academician Gao Fu, director of the Chinese Center for Disease Control and Prevention, stated that he had been injected with an experimental new coronavirus vaccine, hoping to increase public confidence through this move and vaccinate after the vaccine is approved .

Novel Coronavirus Vaccine Technological innovation

Antigenic determinant vaccine/new coronavirus vaccine/innovative production process, features are as follows

 

Target: S protein, catalyzes protective antibodies against viruses, effectively preventing viral diseases

 

1. There are many types of products, common type, enhanced utilization type, long-acting type, long-acting enhanced utilization type

 

2. The process is simple and easy to mass produce

 

3. Modular production, can produce all injections, with adjustable component ratio

 

4. Reasonable selection of excipients

 

Compound amino acid stabilizer and carrier, advantages:

1. good dispersibility, permeability, improve bioavailability

2. Low cost

Whey protein: Slow-release agent, target, control the polymerization speed of insulin analogue and receptor protein, 

3. Adjust the dosage of whey protein, extend the time of medication

4. Reduce the frequency of administration

5. Simple equipment and low investment, promote the entry of SMEs

 6. Can assist in completing pilot and mass production.

 

If approved, relevant entities may forward it to promote mass production of processes and products.

Controversial Events regarding COVID19 Vaccination

On October 9, 2020, in response to the "recommendation on including the new crown pneumonia vaccine in the full reimbursement of medical insurance" put forward by the representative of the National People's Congress, the National Medical Insurance Bureau replied that the level of financing of China's basic medical insurance, especially that of urban and rural residents Low. 

In 2019, the per capita funding for medical insurance for urban and rural residents was only about 800 yuan. However, the number of people for vaccination this time is large, and the total cost is high, which is obviously beyond the capacity of the medical insurance fund. The next step is to work with relevant departments to study the cost of the new crown vaccine.

The world's first SARS-CoV-2 virus inactivated and effective vaccine is rapidly developed

On May 6, the academic journal "Science" published the first publicly reported results of animal experiments on the new crown vaccine. 

The research results were led by the Qin Chuan team from the Institute of Medical Laboratory Animals of the Chinese Academy of Medical Sciences, combined with Zhang Yanjun's team from the Zhejiang Provincial Center for Disease Control and Prevention, Kexing Holding Biotechnology Co., Ltd., Wang Xiangxi's team from the Institute of Biophysics, Chinese Academy of Sciences, and China Institute for Food and Drug Control, China Centers for Disease Control and Prevention, Infectious Disease Prevention and Control Institute and many other units have cooperated to complete the project. 

The title is "Rapid development of aninactivated vaccine for SARS-CoV-2". A preview version was previously released on bioRxiv.

 

Importance of Rapid Development of COVID Vaccines

At present, more than several million cases have been diagnosed in global countries. The most serious case in the United States is more than 1.2 million and the epidemic situation is getting worse. The rapid development of effective vaccines against the new coronavirus disease (COVID-19) is particularly important.

 

The researchers isolated the new coronavirus strains from the bronchoalveolar lavage fluid of 11 patients with confirmed new coronary pneumonia in China, Italy, Switzerland, the United Kingdom, Spain, etc., and 11 samples containing the new coronavirus strains are widely distributed in all available gene sequences Constitution of the phylogenetic tree. 

The researchers selected one of the strains and developed a purified and inactivated SARS-CoV-2 virus vaccine PiCoVacc.

Genetic Stability Test

The genetic stability test showed that PiCoVacc has excellent genetic stability and there is no S mutation that may potentially change the NAb epitope. 

It was found that PiCoVacc can trigger an effective humoral immune response in non-human primates and provide complete protection to the SARS-CoV-2 strain currently raging around the world. 

Through systematic analysis of rhesus monkeys' clinical signs, hematology, and biochemical indicators, researchers believe that the vaccine is safe.

To produce a pilot-scale PiCoVacc for animal research, researchers propagated it in 50 liters of Vero cell culture and inactivated it with β-propiolactone. 

After that, through deep filtration and other means, the research team obtained a high-purity PiCoVacc preparation for experiments.

Based on the above research results, the Chinese National Medical Products Administration has approved the new coronavirus eradication developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. ("Kxing Zhongwei") under Kexing Holding Biotechnology Co., Ltd.

The live vaccine Kerlaifu™️ entered clinical research. Phase I/II clinical research was officially launched in Suining County, Xuzhou City, Jiangsu Province.

Author's Bio

Name: Gwynneth May

Educational Qualification: MBBS, MD (Medicine) Gold Medalist

Profession: Doctor

Experience: 16 Years of Work Experience as a Medical Practitioner

About Me